Back to Search
Start Over
OX40 (CD134) and OX40 ligand, important immune checkpoints in cancer
- Source :
- OncoTargets and Therapy. 12:7347-7353
- Publication Year :
- 2019
- Publisher :
- Informa UK Limited, 2019.
-
Abstract
- Immunotherapy has shown promising results in cancer treatment. Research shows that most patients might be resistant to these therapies. So, new immune therapies are needed. OX40 (CD134) and OX40 ligand (OX40L), costimulatory molecules, express on different types of immune cells. The interaction between OX40 and OX40L (OX40/OX40L) induces the expansion and proliferation of T cells and decreases the immunosuppression of regulatory T (Treg) cells to enhance the immune response to the specific antigen. For the important role OX40 takes in the process of immunity, many clinical trials are focusing on OX40 to find out whether it may have active effects in clinical cancer treatment. The results of clinical trials are still not enough. So, we reviewed the OX40 and its ligand (OX40L) function in cancer, clinical trials with OX40/OX40L and the correlation between OX40/OX40L and other immune checkpoints to add more ideas to tumor feasible treatment.
- Subjects :
- 0301 basic medicine
education.field_of_study
business.industry
medicine.medical_treatment
Cancer
Immunosuppression
Immunotherapy
medicine.disease
OX40 ligand
03 medical and health sciences
030104 developmental biology
0302 clinical medicine
Immune system
Oncology
Antigen
Immunity
030220 oncology & carcinogenesis
medicine
Cancer research
Pharmacology (medical)
CD134
education
business
Subjects
Details
- ISSN :
- 11786930
- Volume :
- 12
- Database :
- OpenAIRE
- Journal :
- OncoTargets and Therapy
- Accession number :
- edsair.doi...........488327778698b2b11271cbf42b2ef29e